Bortezomib Active Not Recruiting Phase 1 Trials for Recurrent Plasma Cell Myeloma / Refractory Plasma Cell Myeloma Treatment

IndicationsStatusPurposePhase
Active Not RecruitingTreatment1
clinicaltrials.gov IdentifierTitleDrugs
NCT02514382Wild-Type Reovirus, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma